A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Related studies linked through entity extraction aliases.